Stock ATXI AVENUE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
4.76 USD -4.99% Intraday chart for Avenue Therapeutics, Inc. -32.70% -60.58%
03-18 Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-22 Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected
Top Midday Gainers
Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Insider Buy: Avenue Therapeutics
Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
MÄRKTE USA/Anleger bleiben in Deckung und warten Quartalszahlen ab
MÄRKTE USA/Anleger mit Blick auf Berichtssaison zurückhaltend
MÄRKTE USA/Uneinheitlich - Goldman Sachs bremst Dow
MÄRKTE USA/Wall Street dürfte Schwung des späten Vortageshandels halten
Avenue Therapeutics Says US FDA Feedback Helps Development of IV Tramadol Study Protocol
Avenue Therapeutics, Inc. Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of Iv Tramadol
Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATXI Stock
  4. News Avenue Therapeutics, Inc.
  5. Other languages